Differentiate your screening program. Grow revenue from every mammogram you already take.
Avera adds a quantitative cardiovascular score to every routine mammogram — no new hardware, no acquisition change, no extra time on the technologist's day. Your center becomes the one in town that reads a woman's heart from a scan she was already coming in for.
Hologic, GE, LORAD — the dominant US mammography base. No retrofit, no new licence on the device.
Anchor pricing for a typical community center. Cash-pay add-ons price ~$40–60 to the patient.
Avera reads the DICOM after acquisition. The tech's day, room turnaround and patient flow are unchanged.
From signed pilot to first scored scan. Manual DICOM uploads work from day one; PACS integration follows. No IT lift on your end past day one.
Adding a cardiovascular read isn't a new procedure. It's a new line item that better serves patients — and a key differentiator for the physicians who refer to you.
Every screening mammogram you already do carries a second signal — the calcified arteries that warn of cardiovascular disease. Avera reads it. You bill it, market it, and refer on it.
A directional model on your actual scan volume. Built to answer the only question that matters before a center signs a pilot: does this make money?
Directional. Assumes 8% severe-tier prevalence in screened population (per published validation). Real engagement varies by market, payer mix and clinical pathway. We'll build a numbers page on your actual data during the pilot brief.
Volume-tiered, billed monthly against scans actually processed. No hardware fee, no per-seat licence, no minimum commitment in pilot.
Indicative pricing. Final per-inference rate set after pilot scoping (PACS, volume, sites, payer mix). Cash-pay collection & downstream referral economics are yours; we charge only the inference fee.
What changes for the technologist, the radiologist, the front desk, the patient — and the cardiology partner you refer to. Spoiler: almost nothing, except a new line on the report and a new conversation at intake.
A one-line addition to your screening consent. Cash-pay add-on, opt-in, $40–60 — or sponsored as part of a women's-health wellness program.
Standard CC and MLO views on the Hologic, GE or LORAD scanner you already operate. No retake, no extra view, no extra dose.
Pulled from PACS after acquisition. Quantitative BAC score in mm² with a severity tier. Returned to the radiology workflow within minutes.
Adjunctive to the mammography read. Severity tier, dated, comparable visit-to-visit — and a templated note for the patient and the referring physician.
Severe-tier patients exit with a one-page patient letter and a templated referral to your cardiology partner. The rest gets logged for the next visit.
A new line item only works if the front desk has a script, the referring OB-GYN has a one-pager, and the patient walks out with something in her hand. Every pilot ships with the full collateral set, co-branded with your center.
Reading-level 6, two languages out of the box, co-branded with your center. Drops into the after-visit packet your front desk already prints.
Print & portal · EN / ESTwo-page PDF for the OB-GYN, primary-care and cardiology offices that send you patients. Built for the desk, not the journal club.
PDF · co-branded · faxableTwo short videos, a printed badge-card, and a Q&A for the five questions patients actually ask. Tested in pilot sites; tuned, not theoretical.
Video · cardstock · 90 secThe clinical-evidence story leans on Emory and Mayo. The commercial story leans on community imaging centers like the ones below — peer sites, by volume and by market.
"It was the first thing I could put on a billboard that the place across town couldn't match. Our OB-GYNs started sending us patients because of the program."
— CRO, mid-sized women's imaging group"We weren't looking for a new clinical claim. We were looking for something real to offer that paid for the marketing it took to bring patients in."
— Operations Director, single-site centerYour patients aren't getting a marketing claim. The model under the hood is the same one published in the European Heart Journal, validated across five sites and three scanner manufacturers. Read the clinical page →
Avera today is for investigational and research-grade deployments. Bunkerhill Health is taking it through FDA clearance; the cleared version comes back to your pilot. The pilot is the path to a first-mover position the cleared rollout will reward.
We're not telling community centers to broadly market a non-cleared device for billing. We are running pilots — research collaborations, IRB-approved screening programs, and sponsored women's-health initiatives — that put you in position to flip on commercial reads the day clearance ships.
IRB-approved screening programs and sponsored wellness initiatives. Per-inference SaaS pricing applies.
Investigational useOur partner files for FDA clearance using the cleared-pathway dossier we've co-authored. Pilots feed real-world performance evidence.
Bunkerhill HealthCleared model licensed back into Avera. Pilot sites flip to commercial reads, broad marketing, and a billing pathway as it matures.
Commercial rolloutWe work alongside ACR and SBI advocates on coding and coverage; pilot sites become the case-study cohort that opens payer doors.
Reimbursement workA 20-minute call, a numbers page on your real volume, and the patient & referrer collateral kit.